Objective: To determine the rate of metastasis and coexistence metastases in patients with advanced prostate cancer in gallium 68 -prostate specific membrane antigen PET/CT (68Ga-PSMA PET/CT). Material and Method: A total of 234 consecutive patients with advanced prostate cancer who underwent 68Ga-PSMA PET/CT were included in this retrospective study. Data on previous treatments, Gleason score, serum Prostate Specific Antigen (PSA) levels (ng/mL) and 68Ga-PSMA PET/CT findings were recorded. Results: The mean age of the patients was 67.6 ± 8.5 years. Median PSA level was 21.7 (0.2-880) ng/ml. Pelvic (41%) and abdominal (30.3%) lymph nodes were the most commonly involved lymph nodes, while bone metastases were multimetastatic and bone carcinomatosis in 22.2% and 30.6% of patients, respectively. Other common distant organ metastases were lung (7.6%) and liver (7.2%) metastases. Level 1-4 lymph node positivity was noted in 29.4%, 33.3% and 6.8% of patients with liver metastasis, lung metastasis and seminal vesicle invasion, respectively. Concomitant lung metastasis was evident in 41.1% of patients with liver metastasis, while lung or liver metastasis was evident in 13.6% of patients with seminal vesicle invasion. Bone metastasis was evident in all patients with liver and lung metastasis, and in 65.9% of patients with seminal vesicle invasion. Conclusion: The findings of this study showed the value of 68Ga-PSMA PET/CT in detecting coexistence rate of metastases in advanced prostate cancer.
Amaç: İleri evre prostat kanserli hastalarda galyum 68 prostat spesifik membran antijen PET/BT (68Ga-PSMA PET/-BT) de saptanan metastaz ile birlikte bulunan metastazların oranlarını saptamak. Gereç ve Yöntem: Bu retrospektif çalışmaya ilerlemiş prostat kanserli 68Ga-PSMA PET-BT çekimi yapılmış 234 hasta dahil edildi. Hastaların önceki tedavileri, Gleason skorları, serum Prostat Spesifik Antijen (PSA) düzeyleri (ng/ml), 68 Ga-PSMA PET/BT bulguları kaydedildi. Bulgular: Hastaların yaş ortalaması 67.6 ± 8.5 yıl bulundu. Ortanca PSA düzeyi 21.7 (0.2-880) ng/ml idi. Pelvik (%41) ve abdominal (%30.3) lenf nodları en sık görülen lenf nodları metastazları iken, kemik metastazları sırasıyla %22.2 ve %30.6 oranında multimetastatik ve kemik karsinomatozisi şeklindeydi. Diğer yaygın uzak organ metastazları akciğer (%7.6) ve karaciğer (%7.2) metastazları idi. Karaciğer metastazı, akciğer metastazı ve seminal vezikül invazyonu olan hastaların sırasıyla %29.4, %33.3 ve %6.8'inde seviye 1-4 lenf nodu pozitifliği saptandı. Karaciğer metastazı olan hastaların %41.1'inde eş zamanlı akciğer metastazı saptanırken, seminal vezikül invazyonu olan hastaların %13.6'sında akciğer veya karaciğer metastazı saptanmıştır. Karaciğer ve akciğer metastazı olan tüm hastalarda ve seminal vezikül invazyonu olan hastaların %65.9'unda kemik metastazı vardı. Sonuç: Bu çalışmanın bulguları, ilerlemiş prostat kanserinde metastazların birlikte bulunma oranlarının saptanmasında 68Ga-PSMA PET/BT'nin değerini göstermiştir.
___
1. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164-87.
2. Stephenson AJ, Kattan MW, Eastha m JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8.
3. Ost P, Decaestecker K, Lambert B, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2013; 74: 297-305.
4. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-883.
5. Henkenberens C, VON Klot CA, Ross TL, et al. 68Ga-PSMA Ligand PET/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy. Anticancer Res 2017; 37: 1273-9.
6. Udovicich C, Perera M, Hofman MS, et al. 68Gaprostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate Int 2017; 5: 125-9.
7. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report? Cancer Imaging 2016; 16: 14.
8. Mottet N, Bellmunt J, Bolla M, et al. EAUESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29.
9. McGrath S, Christidis D, Perera M, et al. Prostate cancer biomarkers: Are we hitting the mark? Prostate Int 2016; 4: 130-5.
10. Graziani T, Ceci F, Castellucci P, et al. (11)Ccholine PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nuc Med Mol Imaging 2016; 43: 1971- 9.
11. Evangelista L, Briganti A, Fanti S, et al. New clinical indications for 18F/11C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016; 70: 161-75.
12. Uprimny C, Kroiss AS, Decristoforo C, et al. 68GaPSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941-9.
13. Kitajima K, Murphy RC, Nathan MA, Sugimura K. Update on positron emission tomography for imaging of prostate cancer. Int J Urol 2014; 21: 12-23.
14. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-95.
15. Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015; 42: 1284-94.
16. McCarthy M, Langton T, Kumar D, Campbell A . Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nuc Med Mol Imaging 2017; 44: 1455-62.
17. Berliner C, Tienken M, Frenzel T, et al . Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. Eur J Nuc Med Mol Imaging 2017; 44: 670-7.
18. Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMAPET/CT in patients with biochemical prostate cancer recurrence and negative 18F-CholinePET/CT. Clin Nuc Med 2016; 41: 515-21.
19. Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44: 960-8.
20. Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 2017; 58:1962-8.
21. Afshar-Oromieh, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
22. Derlin T, Schmuck S, Juhl C, et al. Imaging characteristics and first experience of [68Ga]THPPSMA, a novel probe for rapid kit-based Ga-68 labeling and PET imaging: comparative analysis with [68Ga]PSMA I&T. Mol Imaging Biol 2018 Jan 17. doi: 10.1007/s11307-018-1160-8.
23. Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016; 69: 393-6.
24. Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ. 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging 2017 Oct 29. doi: 10.1111/cpf.12480.
25. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668-74.
26. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397-403.
27. Bubendorf L, Schopher A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1.589 patients. Hum Pathol 2000; 31: 578-83.
28. Pyka T, Weirich G, Einspieler I, et al. 68GaPSMA-HBED-CC PET for differential diagnosis of suggestive of lung lesions in patients with prostate cancer. J Nucl Med 2016; 57: 367-71.
29. Corfield J, Perera M, Bolton D, Lawrentschuk N. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 2018 Jan 17. doi: 10.1007/s00345-018-2182-1.
30. Jilg CA, Drendel V, Rischke HC, et al. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-LigandPET/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics 2017; 7: 1770-80.
31. Sachpekidis C, Bäumer P, Kopka K, et al. 68GaPSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2018 Jan 23. doi: 10.1007/s00259-018-3936-0.
32. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016; 195: 1436-43.
33. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radio-guided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 2015; 68: 530-4.
34. McCarthy M, Langton T, Kumar D, Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nucl Med Mol Imaging 2017; 44: 1455-62.